Accessing CAR-T Therapies
Executive Summary
Infographic: There are two CAR-T therapies on the market, both of which secured their first approvals in 2017. The pipeline of autologous and allogeneic CAR-T options is busy with several candidates in clinical studies. However, getting approval is only one part of getting these breakthrough therapies to patients.
You may also be interested in...
2020 Vision For Biopharma
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.
C-Suite Snippets: Behind The Scenes At Gates Medical Research Institute
In case you missed it: catch up with snippets from interviews recently published by In Vivo.
'Serial Killer’ CAR-T Could Help Autolus Bounce Back
Data presentations at next week’s ASH meeting will be vital for Autolus to restore confidence in pipeline.
Need a specific report? 1000+ reports available
Buy Reports